Registration Dossier

Administrative data

Description of key information

The oral LD50 of CPC is 560 mg/kg bw, and the inhalation LC50 is between 0.054 and 0.51 mg/L or 54 to 510 mg/m3.  The dermal LD50 is greater than 5000 mg/kg bw.

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
560.3 mg/kg bw
Quality of whole database:
adequate

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LC50
54 mg/m³
Quality of whole database:
adequate

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
5 000 mg/kg bw
Quality of whole database:
adequate

Additional information

The oral LD50 of CPC is estimated in an Up-And-Down procedure in rats to be 560.3 mg/kg bw, with lethality observed when doses of 950 mg/kg bw are administered to rats. The inhalation LC50 in rats is between 0.054 and 0.51 mg/L, equivalent to 54 and 510 mg/m3. The dermal LD50 is greater than 5000 mg/kg bw in rats.


Justification for selection of acute toxicity – oral endpoint
experimental result

Justification for selection of acute toxicity – inhalation endpoint
experimental result

Justification for selection of acute toxicity – dermal endpoint
experimental result

Justification for classification or non-classification

The substance is classified for oral and inhalation toxicity according to Regulation EC No. 1272/2008. The oral LD50 of 560.3 mg/kg bw meets the criteria of Acute Toxicity, Category 4 (300 < LD50 < 2000 mg/kg bw). The acute inhalation LC50 is between 0.05 and 0.50 mg/L for dusts/mists, and so classified as Category 2. The substance is not classified for acute dermal toxicity, as the LD50 > 5000 mg/kg bw.